Related Experiment Videos
Novel macrolide-adjustable bidirectional expression modules for coordinated expression of two different transgenes in
Cornelia Fux1, Wilfried Weber, Marie Daoud-El Baba
1Institute of Biotechnology, Swiss Federal Institute of Technology, ETH Zurich, CH-8093 Zurich, Switzerland.
The Journal of Gene Medicine
|December 9, 2003
Summary
Scientists developed a novel bidirectional gene expression system controlled by macrolide antibiotics. This system allows precise, adjustable coregulation of transgenes for gene therapy and biomanufacturing applications.
Area of Science:
- Molecular Biology
- Genetic Engineering
- Biotechnology
Background:
- Precise control of transgene expression is crucial for gene therapy, biopharmaceutical manufacturing, and tissue engineering.
- Current gene expression regulation methods face challenges in maintaining therapeutic windows for clinical gene therapy applications.
Purpose of the Study:
- To design and validate a novel bidirectional expression module for adjustable coregulation of two transgenes.
- To enable macrolide antibiotic-inducible control of gene expression for therapeutic applications.
Main Methods:
- A bidirectional macrolide-responsive promoter was engineered, featuring an operator module (ETR) for a macrolide-dependent transactivator (ET1).
- Minimal promoters (P(hCMVmin); P(hsp70min)) flanking the ETR module drive expression of two divergently oriented transgenes.
- Macrolide antibiotics were used to modulate transactivator binding and adjust transgene expression levels.
Main Results:
- The system demonstrated excellent macrolide-adjustable coregulation of two secreted reporter genes in various cell lines.
- Autoregulated fine-tuning of a single transgene was achieved using a one-vector-based configuration.
- In vivo studies showed coadjustment of erythropoietin (EPO) and secreted alkaline phosphatase (SEAP) levels in mice by administering erythromycin doses.
Conclusions:
- The developed bidirectional, macrolide-responsive expression modules offer precise control over transgene expression.
- These modules are compatible in vivo and represent a significant advancement for targeted, conditional molecular interventions in clinical settings.